101 related articles for article (PubMed ID: 30866168)
1. Why do lung transplant patients discontinue triazole prophylaxis?
Pennington KM; Razonable RR; Peters S; Scott JP; Wylam M; Daly RC; Kennedy CC
Transpl Infect Dis; 2019 Jun; 21(3):e13067. PubMed ID: 30866168
[TBL] [Abstract][Full Text] [Related]
2. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
3. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
[TBL] [Abstract][Full Text] [Related]
4. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD.
Gergis U; Markey K; Greene J; Kharfan-Dabaja M; Field T; Wetzstein G; Schell MJ; Huang Y; Anasetti C; Perkins J
Bone Marrow Transplant; 2010 Apr; 45(4):662-7. PubMed ID: 19684623
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
[TBL] [Abstract][Full Text] [Related]
7. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity.
Mitsani D; Nguyen MH; Shields RK; Toyoda Y; Kwak EJ; Silveira FP; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Clancy CJ
Antimicrob Agents Chemother; 2012 May; 56(5):2371-7. PubMed ID: 22330924
[TBL] [Abstract][Full Text] [Related]
8. Antifungal prophylaxis in lung transplant recipients: A systematic review and meta-analysis.
Pennington KM; Baqir M; Erwin PJ; Razonable RR; Murad MH; Kennedy CC
Transpl Infect Dis; 2020 Aug; 22(4):e13333. PubMed ID: 32449237
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
[TBL] [Abstract][Full Text] [Related]
10. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.
McCreary EK; Davis MR; Narayanan N; Andes DR; Cattaneo D; Christian R; Lewis RE; Watt KM; Wiederhold NP; Johnson MD
Pharmacotherapy; 2023 Oct; 43(10):1043-1050. PubMed ID: 37459118
[TBL] [Abstract][Full Text] [Related]
11. Antifungal Prophylaxis After Lung Transplantation: Where Are We Now?
De Mol W; Bos S; Beeckmans H; Lagrou K; Spriet I; Verleden GM; Vos R
Transplantation; 2021 Dec; 105(12):2538-2545. PubMed ID: 33982907
[TBL] [Abstract][Full Text] [Related]
12. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Dinh A; Savoy JM; Kontoyiannis DP; Takahashi K; Issa GC; Kantarjian HM; DiNardo CD; Rausch CR
Cancer; 2024 Jun; 130(11):1964-1971. PubMed ID: 38340331
[TBL] [Abstract][Full Text] [Related]
13. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.
Kozuch JM; Burt C; Afshar K; Aslam S; Yung G; Mariski M; Golts E; Feist A
Transpl Infect Dis; 2024 Feb; 26(1):e14209. PubMed ID: 38059638
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole prophylaxis in hematologic cancer.
Weiler S; Bellmann R
N Engl J Med; 2007 May; 356(21):2214; author reply 2215-8. PubMed ID: 17522407
[No Abstract] [Full Text] [Related]
15. A novel approach to reducing hepatotoxicity related to fungal prophylaxis in pediatric lung transplant recipients.
Patz-Sobczak C; Young J; Bunton D; Kuklinski C; Estabrook M
Pediatr Transplant; 2024 May; 28(3):e14740. PubMed ID: 38616325
[TBL] [Abstract][Full Text] [Related]
16. Optimizing antifungal prophylaxis in allogeneic stem cell transplantation: A cohort study of two different approaches.
Selby PR; Warner MS; Peake SL; Bardy P; Hiwase D; Singhal D; Beligaswatte A; Hahn U; Roberts JA; Yeung D; Shakib S
Transpl Infect Dis; 2022 Dec; 24(6):e13988. PubMed ID: 36349869
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis.
Olum R; Baluku JB; Kazibwe A; Russell L; Bongomin F
PLoS One; 2020; 15(10):e0240374. PubMed ID: 33052954
[TBL] [Abstract][Full Text] [Related]
18. Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results From a Subgroup Analysis of a Multicenter National Registry.
Nguyen MH; Ostrosky-Zeichner L; Pappas PG; Walsh TJ; Bubalo J; Alexander BD; Miceli MH; Jiang J; Song Y; Thompson GR
Open Forum Infect Dis; 2023 Sep; 10(9):ofad424. PubMed ID: 37674634
[TBL] [Abstract][Full Text] [Related]
19. Itraconazole and Voriconazole: The Complexity of Dose Adjustments.
Ito H; Ogawa R
Clin Infect Dis; 2022 Aug; 75(3):552. PubMed ID: 35092680
[No Abstract] [Full Text] [Related]
20. Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.
Gastine SE; Rauwolf KK; Pieper S; Hempel G; Lehrnbecher T; Tragiannidis A; Groll AH
Mycoses; 2023 Nov; 66(11):969-976. PubMed ID: 37553971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
